Skip to main content

Table 4 Baseline characteristics and demographics for patients enrolled in phase 2 (n = 33)a

From: Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies

  Pacritinib 400 mg
n = 33b
Median age, years (range) 67.0 (47–83)
Male, n (%) 22 (66.7)
Median time from initial diagnosis, months (range) 31.8 (0.3–210.0)
Median prior systemic therapies, n (range) 1 (0–4)
Median time since last MF treatmentc, months (range) 1.68 (0.6-36.4)
ECOG PS, n (%)
 0 6 (18.2)
 1 19 (57.6)
 2 8 (24.2)
JAK2 mutationd, n (%) 27 (81.8)
Type of myelofibrosis, n (%)
 Primary myelofibrosis 17 (51.5)
 Post-polycythemia vera myelofibrosis 12 (36.4)
 Post-essential thrombocythemia myelofibrosis 4 (12.1)
Current Lille Score, n (%)
 High risk 1 (3.0)
 Intermediate risk 7 (21.2)
 Low risk 2 (6.1)
 Missinge 23 (69.7)
Current DIPSS risk category, n (%)
 High risk 7 (21.2)
 Intermediate-2 risk 9 (27.3)
 Intermediate-1 risk 3 (9.1)
 Indeterminatef 14 (42.4)
Hemoglobin
 Mediang, g/L (range) 90.0 (37–144)
 Grade 0–2, n (%) 27 (81.8)
 Grade 3, n (%) 6 (18.2)
 Baseline hemoglobin level, n (%)
   <10 g/L 20 (60.6)
   <8 g/L 6 (18.2)
 RBC-transfusion dependentg, n (%) 6 (19.4)
Platelets
 Mediang, ×109/L (range) 126.0 (28–494)
 Grade 0–2, n (%) 29 (87.9)
 Grade 3, n (%) 4 (12.1)
 Baseline platelet count, n (%)
   <100 × 109/L 10 (42.4)
   <50 × 109/L 4 (12.1)
 Platelet-transfusion dependentg, n (%) 0
Leukocytes
 Mediang, ×109/L (range) 8.91 (1.5–38.2)
 Grade 0–2, n (%) 31 (93.9)
 Grade 3, n (%) 2 (6.1)
 Baseline leukocyte count >25 × 109/L, n (%) 3 (9.1)
  1. aTwo patients enrolled in the study did not receive the study drug: one patient withdrew consent before beginning treatment and the second patient was unable to undergo magnetic resonance imaging (one of the eligibility criteria)
  2. b97% of patients were white
  3. cIn patients who had received prior treatment (n = 25)
  4. dAll JAK2 mutations were V617F
  5. eCase report forms were designed for direct entry of Lille score by sites; however, some versions of the forms were missing the field for entry of Lille score
  6. fUnable to calculate DIPSS risk category due to missing baseline peripheral blood blasts
  7. gIn the safety population (n = 31)
  8. DIPSS Dynamic International Prognostic Scoring System, ECOG PS Eastern Cooperative Oncology Group Performance Status